MRCP UK EXAMINATIONS

Detailed explanation-1: -Ivacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) potentiators. It works by improving the function of a protein in the body to decrease the build-up of thick mucus in the lungs and improving other symptoms of cystic fibrosis.

Detailed explanation-2: -KALYDECO is for people with cystic fibrosis (CF) age 4 months and older with at least one mutation in their CF gene that is responsive to KALYDECO. Enter your mutations to see if at least one of them is eligible. Most people with CF have 2 CF mutations, 1 on each copy of the CF gene.

Detailed explanation-3: -Ivacaftor is a CFTR potentiator shown to increase chloride transport by activated CFTR channels at the cell surface in vitro. G551D-CFTR (c. 1652G > A) is the most common gating mutation associated with CF disease, having an allelic frequency of only approximately 2.2%.